GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanjing Medlander Medical Technology Co Ltd (SHSE:688273) » Definitions » EBIT

Nanjing Medlander Medical Technology Co (SHSE:688273) EBIT : ¥120.6 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nanjing Medlander Medical Technology Co EBIT?

Nanjing Medlander Medical Technology Co's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was ¥43.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was ¥120.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nanjing Medlander Medical Technology Co's annualized ROC % for the quarter that ended in Jun. 2024 was 28.30%. Nanjing Medlander Medical Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 69.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nanjing Medlander Medical Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 11.62%.


Nanjing Medlander Medical Technology Co EBIT Historical Data

The historical data trend for Nanjing Medlander Medical Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Medlander Medical Technology Co EBIT Chart

Nanjing Medlander Medical Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 116.09 138.37 129.89 146.20 101.86

Nanjing Medlander Medical Technology Co Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.98 30.83 4.13 42.24 43.43

Competitive Comparison of Nanjing Medlander Medical Technology Co's EBIT

For the Medical Devices subindustry, Nanjing Medlander Medical Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing Medlander Medical Technology Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Medlander Medical Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nanjing Medlander Medical Technology Co's EV-to-EBIT falls into.



Nanjing Medlander Medical Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥120.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanjing Medlander Medical Technology Co  (SHSE:688273) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nanjing Medlander Medical Technology Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=165.16 * ( 1 - 12.62% )/( (505.061 + 514.852)/ 2 )
=144.316808/509.9565
=28.30 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1554.515 - 64.55 - ( 1024.784 - max(0, 122.444 - 1107.348+1024.784))
=505.061

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1538.821 - 60.355 - ( 991.291 - max(0, 114.859 - 1078.473+991.291))
=514.852

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Nanjing Medlander Medical Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=173.724/( ( (250.165 + max(-28.953, 0)) + (250.71 + max(-14.439, 0)) )/ 2 )
=173.724/( ( 250.165 + 250.71 )/ 2 )
=173.724/250.4375
=69.37 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(18.478 + 50.146 + 12.155) - (64.55 + 0 + 45.182)
=-28.953

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17.811 + 52.855 + 14.965) - (60.355 + 0 + 39.715)
=-14.439

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nanjing Medlander Medical Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=120.632/1037.874
=11.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanjing Medlander Medical Technology Co EBIT Related Terms

Thank you for viewing the detailed overview of Nanjing Medlander Medical Technology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanjing Medlander Medical Technology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 2, Gande Road, 2nd Floor, Building 5, Jiangning High-tech Park, Jiangning District, Jiangsu Province, Nanjing City, CHN, 211100
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales and service of related products in the field of pelvic floor and postpartum rehabilitation.
Executives
Zhu Bi Sheng senior management
Chen Jiang Ning senior management
Yang Rui Jia Directors, senior managers, core technical personn
Shi Zhi Huai Directors, senior managers, core technical personn
Chen Bin Directors, senior managers
Tu Hong Lin Directors, senior managers
Wang Wang senior management

Nanjing Medlander Medical Technology Co Headlines

No Headlines